Opthea Reports Full-Year Financial Results and Business Updates
August 30, 2024
OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO(TM) Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma
July 6, 2021
Related Post
-
-
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
August 22, 2024
-
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
August 20, 2024
-
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
August 12, 2024